Gene Therapy Market Size, Share and Forecast (2019-2026)

SKU: DHC158 | Last Updated On: 2019-07-02 | No. of Pages: 212 | Available Formats

( 31 Samples have been requested. )
In May 2019, AveXis received the FDA approval for Zolgensma®, the first and only gene therapy for pediatric patients with spinal muscular atrophy (SMA).

Gene Therapy Market

The global gene therapy market size was worth $ XX billion in2018 and is forecasted to reach $ XX billion by 2026, at a CAGR of XX% during the forecast period.
Gene therapy is introduction of DNA into a patient to treat a genetic disease. The new DNA usually contains a functioning gene to correct the effects of a disease-causing mutation. Researchers are studying gene therapy for a number of diseases such as severe combined immune deficiencies, hemophilia, Parkinson's disease, cancer and even HIV through a number of approaches.

Gene Therapy Market Dynamics

Advancements in treatments to cure diseases such as cancer, neuro, and cardio diseases are driving the global gene therapy market in recent years and anticipated to remain the same over the forecast period. For instance, in 2017, in France, researchers from Bluebird Bio announced that a teenage boy in France had been cured of sickle-cell disease after receiving experimental gene therapy. Scientists removed stem cells from the boy’s bone marrow and modified them in the lab by introducing copies of a gene to prevent his red blood cells from becoming sickled. 
Rising prevalence of chronic diseases such as cancer, asthma, diabetes, and COPD are boosting the requirement of gene therapy over the forecast period. For instance, according to the National Cancer Institute in 2018, in the United States, an estimated 1,735,350 new cases of cancer will be diagnosed and 609,640 people will die from the disease.
Increasing number of gene therapy start-ups in 2019 is expected to be one of the major factors driving the growth of the market during the forecast period (2019-2026). For instance, in January 2019, Apic Bio launched with $40 million to treat ALS and liver diseases. Also, Neurogene launched with $68.5 million to tackle several neurological and lysosomal storage disorder diseases.
However, the high cost of gene therapies and stringent regulatory framework are hampering the global gene therapy market over the forecast period. The cost of these therapies can be extremely expensive and present a large burden to the healthcare system, in the range of $400,000 to $850,000 at the high end, currently, for the approved gene therapies, and could be amplified depending on the size of the patient population. According to estimates from the Institute for Clinical and Economic Review, if gene therapies were used just by one in 10 patients who had a genetic condition, the cumulative budget impact of therapies priced at $1m–$2m (which some may consider an overestimate now) could reach $3tn in the US alone. 
As the pipeline advances, the demand grows which leads gene therapy developers to turn towards contract manufacturing organizations (CMOs) or contract development and manufacturing organizations (CDMOs) for vector supply services. The demand for manufacturing will provide lucrative opportunities for CMOs and CDMOs in the specialized market of cell and gene therapy, but that demand will likely exceed the supply. 

Gene Therapy Market Segmentation Analysis

Based on application, the global gene therapy market is segmented into oncology, neurological diseases, inherited diseases, cardiac diseases, and infectious diseases. Oncology had the highest market share in 2018 and expected to remain dominant same over the forecast period.  One-third of the gene therapy pipeline consists of candidates in development for cancer. About 43% of the rare disease gene therapy pipeline is considered rare oncologic diseases. Cancers for which gene therapy products are being developed include glioblastoma, metastatic melanoma, head and neck cancer, prostate cancer, renal cell cancer, and colorectal cancer. For instance, in 2017, FDA approved gene therapy treatment for cancer known as CAR-T therapy. The therapy is designed to treat an often-lethal type of blood and bone marrow cancer that affects children and young adults and will be sold by Novartis for $475,000. 
Gene therapy applications in cardio diseases have the second largest share in recent years due to increasing number of heart-related diseases. According to the World Health Organization in 2017, 17.9 million people died from CVDs in 2016 globally, representing 31% of all global deaths. Researchers and scientists are has been working effectively on gene therapy in cardiology areas to provide solutions.
Based on therapy type, the global gene therapy market is categorized into somatic gene therapy and germline gene therapy. In somatic gene therapy, transfer of a section of DNA to any cell of the body that doesn’t produce sperm or eggs whereas in germline gene therapy, transfer of a section of DNA to cells that produce eggs or sperm.

Global Gene Therapy Market, 2017-2026, in USD Million

 

Global Gene Therapy Market Geographical Share

North America holds the dominant market share for plasma fractionation in 2018, and it is expected to maintain the growth over the forecast period, owing to the rapid advancements in gene therapy market. For instance, in 2018, Spark Therapeutics developed Luxturna that was approved by the Food and Drug Administration (FDA) for treatment of RPE65-mediated inherited retinal dystrophy. Luxturna is the first targeted gene therapy approved in the US, representing a huge milestone in medical care. The American Society of Clinical Oncology’s (ASCO), Clinical Cancer Advances Report 2018 recently named adoptive immunotherapy with chimeric antigen receptor T cells (CART T as the most clinical advance of the year.)
Europe has the second largest market share in global gene therapy market due to increasing number of chronic diseases such as cancer and heart attack. According to the WHO, with more than 3.7 million new cases and 1.9 million deaths each year, cancer represents the second most important cause of death and morbidity in Europe. Hence, rising research and development for the treatment of the chronic diseases, the market for gene therapy is growing in this region.
Hemophilia is a challenging market by biotechs across Europe and North America competing to launch the first gene therapy. Gene therapy emerges as a potential new treatment for patients with hemophilia. In July 2019, the International Society on Thrombosis and Haemostasis (ISTH) launched the Gene Therapy in Hemophilia: An ISTH Education Initiative. The France Foundation collaborated with the ISTH to educate clinicians around the world about the science and potential role of gene therapy for patients with hemophilia.

Global Gene Therapy Market By Geography, 2018

Global Gene Therapy Market – Competitive Analysis

Key pharmaceutical companies are investing significant money in the clinical research and development of gene therapy products. Competition is immense in global gene therapy market and companies see a huge opportunity in gene therapy market.
The key players in gene therapy market are Novartis AG, UniQure N.V, Spark Therapeutics LLC, Bluebird Bio, Kite Pharmaceuticals, Gilead Sciences, Inc, Human Stem Cell Institute, Shire Plc, Cellectis and GlaxoSmithKline plc.
Partnerships provide an important vehicle for both the licenser and licensee to grow. Over the 2012–18 time period (through September 2018), 351 gene therapy alliances were signed, with a total deal value of $41bn. The players are adopting various key strategies such as product launches, investments, mergers & acquisitions which are leading to expand their business globally, hence contributing to the growth of the gene therapy market. For instance,
In May 2019, Novartis, a Swiss pharmaceutical company received the US regulatory approval for a gene therapy that treats a rare childhood disorder and has a price tag of US$2.1 million, making it the most expensive drug in history.
In May 2019, ElevateBio raised $150 million to launch cell and gene therapy incubator.
On February 15, 2019, Gene therapy pioneer James Wilson launches startup Passage Bio with $115.5 million. It has raised $115.5 million in series financing to develop gene therapies for rare genetic diseases of the central nervous system.
In 2019, Novartis has a deal with Spark to market Luxturna in Europe, and is therefore at the forefront of not only the groundbreaking R&D behind cell and gene therapy, but is also looking to lead the revolution in pricing and reimbursement required to make them a commercial success.

Why Purchase the Report?

·      Visualize the composition of the gene therapy market across each indication, in terms of therapy type, application type highlighting the key commercial assets and players.

·      Identify commercial opportunities in the gene therapy market by analyzing trends and co-development deals.

·      Excel data sheet with thousands of data points of the gene therapy market-level 4/5 segmentation.

·      A PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.

·      Product mapping in excel for the key product of all major market players

Target Audience

• Service Providers/ Buyers

• Industry Investors/Investment Bankers

• Education & Research Institutes

• Research Professionals

• Emerging Companies

• Manufacturers    

Gene Therapy Market

  1. Global Gene Therapy Market Methodology and Scope

    1. Research methodology

    2. Research Objective and Scope of the Report

  2. Global Gene Therapy Market – Market Definition and Overview

  3. Global Gene Therapy Market – Executive Summary

    1. Market Snippet by Therapy Type

    2. Market Snippet by Application Type

    3. Market Snippet by Region

  4. Global Gene Therapy Market Dynamics

    1. Market Impacting Factors

      1. Drivers

        1. Increasing Technological advancements

        2. Increasing Number of Chronic Diseases

      2. Restraints

        1. High Cost Of Treatments

      3. Impact Analysis

  5. Global Gene Therapy Market – Industry Analysis

    1. Porter's Five Forces Analysis

    2. End User Perspective

    3. Pricing Analysis

  6. Global Gene Therapy Market – by Therapy Type

    1. Introduction

      1. Market Size Analysis, and Y-o-Y Growth Analysis (%), by Therapy Type

      2. Market Attractiveness Index, by Therapy Type

    2. Somatic Gene Therapy

      1. Introduction

      2. Market Size Analysis, and Y-o-Y Growth Analysis (%)

    3. Germline Therapy

  7. Global Gene Therapy Market – By Application Type

    1. Introduction

      1. Market Size Analysis, and Y-o-Y Growth Analysis (%), by Application Type

      2. Market Attractiveness Index, by Application Type

    2. Cardio *

      1. Introduction

      2. Market Size Analysis, and Y-o-Y Growth Analysis (%)

    3. Neuro

    4. Oncology

    5. Infectious Diseases

    6. Inherited Diseases

    7. Others

  8. Global Gene Therapy Market – By Region

    1. Introduction

      1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Region

      2. Market Attractiveness Index, By Region

    2. North America

      1. Introduction

      2. Key Region-Specific Dynamics

      3. Market Size Analysis, and Y-o-Y Growth Analysis (%), by Therapy Type

      4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application Type

      5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Countries

        1. U.S.

        2. Canada

        3. Mexico

    3. Europe

      1. Introduction

      2. Key Region-Specific Dynamics

      3. Market Size Analysis, and Y-o-Y Growth Analysis (%), by Therapy Type

      4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application Type

      5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Countries

        1. Germany

        2. U.K.

        3. France

        4. Italy

        5. Spain

        6. Rest of Europe

    4. South America

      1. Introduction

      2. Key Region-Specific Dynamics

      3. Market Size Analysis, and Y-o-Y Growth Analysis (%), by Therapy Type

      4. Market Size Analysis, and Y-o-Y Growth Analysis (%), by Application Type

      5. Market Size Analysis, and Y-o-Y Growth Analysis (%), by Countries

        1. Brazil

        2. Argentina

        3. Rest of South America

    5. Asia Pacific

      1. Introduction

      2. Key Region-Specific Dynamics

      3. Market Size Analysis, and Y-o-Y Growth Analysis (%), by Therapy Type

      4. Market Size Analysis, and Y-o-Y Growth Analysis (%), by Application Type

      5. Market Size Analysis, and Y-o-Y Growth Analysis (%), by Countries

        1. China

        2. India

        3. Japan

        4. Australia

        5. Rest of Asia Pacific

    6. Middle East and Africa

      1. Introduction

      2. Key Region-Specific Dynamics

      3. Market Size Analysis, and Y-o-Y Growth Analysis (%), by Therapy Type

      4. Market Size Analysis, and Y-o-Y Growth Analysis (%), by Application Type

  9. Global Gene Therapy Market – Competitive Landscape

    1. Competitive Scenario

    2. Competitor Strategy Analysis

    3. Comparative Therapy Portfolio Analysis

    4. Market Positioning/Share Analysis

    5. Mergers and Acquisitions Analysis

  10. Company Profiles

    1. Novartis*

      1. Company overview

      2. Therapy portfolio and description

      3. Key highlights

      4. Financial overview

    2. UniQure N.V

    3. Spark Therapeutics LLC

    4. Bluebird Bio

    5. Kite Pharmaceuticals

    6. Gilead Sciences, Inc

    7. Human Stem Cell Institute

    8. Shire Plc

    9. Cellectis

    10. GlaxoSmithKline plc

  11. Global Gene Therapy Market – Premium Insights

  12. Global Gene Therapy Market – DataM

    1. Appendix

    2. List of Tables and Figures

    3. About Us and Services

    4. Contact Us

List of Tables

Table 1 Global Gene Therapy Market Value, By Type, 2018,2022 & 2026 ($ Million)

Table 2 Global Gene Therapy Market Value, By Application, 2018,2022 & 2026 ($ Million)

Table 3 Global Gene Therapy Market Value, By Gene Type, 2018,2022 & 2026 ($ Million)

Table 4 Global Gene Therapy Market Value, By Region, 2018,2022 & 2026 ($ Million)

Table 5 Global Gene Therapy Market Value, By Type, 2018,2022 & 2026 ($ Million)

Table 6 Global Gene Therapy Market Value, By Type, 2017-2026 ($ Million)

Table 7 Global Gene Therapy Market Value, By Application, 2018,2022 & 2026 ($ Million)

Table 8 Global Gene Therapy Market Value, By Application, 2017-2026 ($ Million)

Table 9 Global Gene Therapy Market Value, By Gene Type, 2018,2022 & 2026 ($ Million)

Table 10 Global Gene Therapy Market Value, By Gene Type, 2017-2026 ($ Million)

Table 11 Global Gene Therapy Market Value, By Region, 2018,2022 & 2026 ($ Million)

Table 12 Global Gene Therapy Market Value, By Region, 2017-2026 ($ Million)

Table 13 North America Gene Therapy Market Value, By Type, 2017-2026 ($ Million)

Table 14 North America Gene Therapy Market Value, By Application, 2017-2026 ($ Million)

Table 15 North America Gene Therapy Market Value, By Gene Type, 2017-2026 ($ Million)

Table 16 North America Gene Therapy Market Value, By Country, 2017-2026 ($ Million)

Table 17 South America Gene Therapy Market Value, By Type, 2017-2026 ($ Million)

Table 18 South America Gene Therapy Market Value, By Application, 2017-2026 ($ Million)

Table 19 South America Gene Therapy Market Value, By Gene Type, 2017-2026 ($ Million)

Table 20 South America Gene Therapy Market Value, By Country, 2017-2026 ($ Million)

Table 21 Europe Gene Therapy Market Value, By Type, 2017-2026 ($ Million)

Table 22 Europe Gene Therapy Market Value, By Application, 2017-2026 ($ Million)

Table 23 Europe Gene Therapy Market Value, By Gene Type, 2017-2026 ($ Million)

Table 24 Europe Gene Therapy Market Value, By Country, 2017-2026 ($ Million)

Table 25 Asia-Pacific Gene Therapy Market Value, By Type, 2017-2026 ($ Million)

Table 26 Asia-Pacific Gene Therapy Market Value, By Application, 2017-2026 ($ Million)

Table 27 Asia-Pacific Gene Therapy Market Value, By Gene Type, 2017-2026 ($ Million)

Table 28 Asia-Pacific Gene Therapy Market Value, By Country, 2017-2026 ($ Million)

Table 29 Middle East & Africa Gene Therapy Market Value, By Type, 2017-2026 ($ Million)

Table 30 Middle East & Africa Gene Therapy Market Value, By Application, 2017-2026 ($ Million)

Table 31 Middle East & Africa Gene Therapy Market Value, By Gene Type, 2017-2026 ($ Million)

Table 32 Novartis: Overview

Table 33 Novartis: Product Portfolio

Table 34 Novartis: Key Developments

Table 35 UniQure N.V: Overview

Table 36 UniQure N.V: Product Portfolio

Table 37 UniQure N.V: Key Developments

Table 38 Spark Therapeutics LLC: Overview

Table 39 Spark Therapeutics LLC: Product Portfolio

Table 40 Spark Therapeutics LLC: Key Developments

Table 41 Bluebird Bio: Overview

Table 42 Bluebird Bio: Product Portfolio

Table 43 Bluebird Bio: Key Developments

Table 44 Kite Pharmaceuticals: Overview

Table 45 Kite Pharmaceuticals: Product Portfolio

Table 46 Kite Pharmaceuticals: Key Developments

Table 47 Gilead Sciences, Inc: Overview

Table 48 Gilead Sciences, Inc: Product Portfolio

Table 49 Gilead Sciences, Inc: Key Developments

Table 50 Human Stem Cell Institute: Overview

Table 51 Human Stem Cell Institute: Product Portfolio

Table 52 Human Stem Cell Institute: Key Developments

Table 53 Shire Plc: Overview

Table 54 Shire Plc: Product Portfolio

Table 55 Shire Plc: Key Developments

Table 56 Cellectis : Overview

Table 57 Cellectis : Product Portfolio

Table 58 Cellectis : Key Developments

Table 59 GlaxoSmithKline plc: Overview

Table 60 GlaxoSmithKline plc: Product Portfolio

Table 61 GlaxoSmithKline plc: Key Developments 

List of Figures

Figure 1 Global Gene Therapy Market Share, By Type, 2018 & 2026 (%)

Figure 2 Global Gene Therapy Market Share, By Application, 2018 & 2026 (%)

Figure 3 Global Gene Therapy Market Share, By Gene Type, 2018 & 2026 (%)

Figure 4 Global Gene Therapy Market Share, By Region, 2018 & 2026 (%)

Figure 5 Global Gene Therapy Market Value, 2017-2026 ($ Million)

Figure 6 Global Gene Therapy Market Y-o-Y Growth, By Type, 2018-2026 (%)

Figure 7 Vector: Global Gene Therapy Market Value, 2017-2026 ($ Million)

Figure 8 Non Vector: Global Gene Therapy Market Value, 2017-2026 ($ Million)

Figure 9 Global Gene Therapy Market Y-o-Y Growth, By Application, 2018-2026 (%)

Figure 10 Cardio: Global Gene Therapy Market Value, 2017-2026 ($ Million)

Figure 11 Neuro: Global Gene Therapy Market Value, 2017-2026 ($ Million)

Figure 12 Oncology: Global Gene Therapy Market Value, 2017-2026 ($ Million)

Figure 13 Infectious Diseases: Global Gene Therapy Market Value, 2017-2026 ($ Million)

Figure 14 Inherited Diseases: Global Gene Therapy Market Value, 2017-2026 ($ Million)

Figure 15 Others: Global Gene Therapy Market Value, 2017-2026 ($ Million)

Figure 16 Global Gene Therapy Market Y-o-Y Growth, By Gene Type, 2018-2026 (%)

Figure 17 Antigen: Global Gene Therapy Market Value, 2017-2026 ($ Million)

Figure 18 Cytokine: Global Gene Therapy Market Value, 2017-2026 ($ Million)

Figure 19 Tumor suppressor: Global Gene Therapy Market Value, 2017-2026 ($ Million)

Figure 20 Suicide: Global Gene Therapy Market Value, 2017-2026 ($ Million)

Figure 21 Deficiency: Global Gene Therapy Market Value, 2017-2026 ($ Million)

Figure 22 Growth factors: Global Gene Therapy Market Value, 2017-2026 ($ Million)

Figure 23 Receptors: Global Gene Therapy Market Value, 2017-2026 ($ Million)

Figure 24 Others: Global Gene Therapy Market Value, 2017-2026 ($ Million)

Figure 25 Global Gene Therapy Market Y-o-Y Growth, By Region, 2018-2026 (%)

Figure 26 North America Gene Therapy Market Value, 2017-2026 ($ Million)

Figure 27 North America Gene Therapy Market Share, By Type, 2018 & 2026 (%)

Figure 28 North America Gene Therapy Market Share, By Application, 2018 & 2026 (%)

Figure 29 North America Gene Therapy Market Share, By Gene Type, 2018 & 2026 (%)

Figure 30 North America Gene Therapy Market Share, By Country, 2018 & 2026 (%)

Figure 31 South America Gene Therapy Market Value, 2017-2026 ($ Million)

Figure 32 South America Gene Therapy Market Share, By Type, 2018 & 2026 (%)

Figure 33 South America Gene Therapy Market Share, By Application, 2018 & 2026 (%)

Figure 34 South America Gene Therapy Market Share, By Gene Type, 2018 & 2026 (%)

Figure 35 South America Gene Therapy Market Share, By Country, 2018 & 2026 (%)

Figure 36 Europe Gene Therapy Market Value, 2017-2026 ($ Million)

Figure 37 Europe Gene Therapy Market Share, By Type, 2018 & 2026 (%)

Figure 38 Europe Gene Therapy Market Share, By Application, 2018 & 2026 (%)

Figure 39 Europe Gene Therapy Market Share, By Gene Type, 2018 & 2026 (%)

Figure 40 Europe Gene Therapy Market Share, By Country, 2018 & 2026 (%)

Figure 41 Asia-Pacific Gene Therapy Market Value, 2017-2026 ($ Million)

Figure 42 Asia-Pacific Gene Therapy Market Share, By Type, 2018 & 2026 (%)

Figure 43 Asia-Pacific Gene Therapy Market Share, By Application, 2018 & 2026 (%)

Figure 44 Asia-Pacific Gene Therapy Market Share, By Gene Type, 2018 & 2026 (%)

Figure 45 Asia-Pacific Gene Therapy Market Share, By Country, 2018 & 2026 (%)

Figure 46 Middle East & Africa Gene Therapy Market Value, 2017-2026 ($ Million)

Figure 47 Middle East & Africa Gene Therapy Market Share, By Type, 2018 & 2026 (%)

Figure 48 Middle East & Africa Gene Therapy Market Share, By Application, 2018 & 2026 (%)

Figure 49 Middle East & Africa Gene Therapy Market Share, By Gene Type, 2018 & 2026 (%)

Figure 50 Novartis: Financials

Figure 51 UniQure N.V: Financials

Figure 52 Spark Therapeutics LLC: Financials

Figure 53 Bluebird Bio: Financials

Figure 54 Kite Pharmaceuticals: Financials

Figure 55 Gilead Sciences, Inc: Financials

Figure 56 Human Stem Cell Institute: Financials

Figure 57 Shire Plc: Financials

Figure 58 Cellectis : Financials

Figure 59 GlaxoSmithKline plc: Financials

Did not find what you were looking for?Every 7 out of 10 customers request tailored reports. Get yours today!
step 1We collate your requirements.
step 2Our global research team is put into action.
step 3We deliver, and make sure your endeavour is a success!

Buy This Report